Page 21 - ஸிம்மர் பயோமெட் ஹோல்டிங்ஸ் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zimmer Biomet : Announces First Quarter 2021 Financial Results and Full Year Revenue Outlook

Message : Required fields WARSAW, Ind., May 4, 2021 /PRNewswire/ Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2021. The Company reported first quarter net sales of $1.847 billion, an increase of 3.6% over the prior year period, and an increase of 0.8% on a constant currency basis. Net earnings for the first quarter were $198.1 million, or $359.1 million on an adjusted basis. Diluted earnings per share were $0.94 for the first quarter. Adjusted diluted earnings per share were $1.71 for the first quarter, an increase of 0.6% over the prior year period. Our performance was stronger than we anticipated in the first quarter, as we saw signs of the pandemic beginning to subside across many regions toward the end of the quarter driven by acceleration of vaccine rollout. As we move into the second quarter, we expect that momentum to continue and believe we are well-positioned to meet the needs of our

United statesBryan hansonZimmer biometEllie humphreyLori winklerAsia pacificIvan tornoDrug administrationForeign currency exchange impactExchange commissionSang yi to groupEuropean unionZimmer biomet holdings incZimmer biomet leadership teamEuropean union medical device regulationZimmer biomet holdings

Zimmer: Q1 Earnings Snapshot

Zimmer: Q1 Earnings Snapshot FacebookTwitterEmail WARSAW, Ind. (AP) Zimmer Biomet Holdings Inc. (ZBH) on Tuesday reported first-quarter net income of $198.1 million, after reporting a loss in the same period a year earlier. The Warsaw, Indiana-based company said it had net income of 94 cents per share. Earnings, adjusted for amortization costs and restructuring costs, were $1.71 per share. The results exceeded Wall Street expectations. The average estimate of 14 analysts surveyed by Zacks Investment Research was for earnings of $1.51 per share. The orthopedic device maker posted revenue of $1.85 billion in the period, also beating Street forecasts. Eleven analysts surveyed by Zacks expected $1.74 billion.

United statesZacks investment researchZimmer biomet holdings incZimmer biomet holdingsWall streetAutomated insightsZacks investmentUnited statesNorth americaC complete state nationalIndiana state1 earnings snapshotF wireAutomated insightsWall streetஒன்றுபட்டது மாநிலங்களில்

Zimmer Biomet Reinitiates FY21 Outlook

Zimmer Biomet Reinitiates FY21 Outlook WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Tuesday, musculoskeletal healthcare firm Zimmer Biomet Holdings Inc. (ZBH) re-initiated its adjusted earnings and revenue growth outlook for the full-year 2021. For fiscal 2021, the company now expects adjusted earnings in a range of $7.60 to $8.00 per share on projected revenue growth of 14 to 17 percent from last year on a reported basis. On average, analysts polled by Thomson Reuters expect the company to report earnings of $7.72 per share on revenue growth of 13.5 percent to $7.97 billion for the year. Analysts estimates typically exclude special items. Copyright RTT News/dpa-AFX

United statesThomson reutersZimmer biomet holdings incZimmer biomet holdingsஒன்றுபட்டது மாநிலங்களில்தாம்சன் ராய்ட்டர்ஸ்ஸிம்மர் பயோமெட் ஹோல்டிங்ஸ் இன்க்ஸிம்மர் பயோமெட் ஹோல்டிங்ஸ்

Zimmer Biomet (NYSE:ZBH) - Zimmer Biomet Stock Dips Despite Q1 Earnings Beat, Better-Than-Expected Guidance

Zimmer Biomet (NYSE:ZBH) - Zimmer Biomet Stock Dips Despite Q1 Earnings Beat, Better-Than-Expected Guidance
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Suketu upadhyayZimmer biometZimmer biomet holdings incWall streetMiddle eastBiomet presidentசூக்கேத்து உபாதியாய்ஸிம்மர் பயோமெட்ஸிம்மர் பயோமெட் ஹோல்டிங்ஸ் இன்க்சுவர் தெருநடுத்தர கிழக்கு

United States Hip Reconstruction Market Report 2021, Featuring Zimmer Biomet Holdings Inc , Johnson & Johnson, Stryker Corporation and Smith & Nephew plc

Share this article Share this article ResearchAndMarkets.com s offering. The U.S. hip reconstruction market has increased at a significant CAGR over the years and projections are made that the market will rise in the next four years i.e. 2021-2025 tremendously. The hip reconstruction market is expected to increase due to aging population, growing prevalence of arthritis, increasing obesity, growth in chronic diseases, escalating healthcare expenditure, etc. Yet the market faces some challenges such as high cost involved, regulatory risk, etc. The hip reconstruction market can be segmented on the basis of type. There are four major types of hip reconstruction procedures: Primary Total Hip Reconstruction, Partial Hip Reconstruction, Hip Resurfacing and Revision Hip Reconstruction. Primary Total Hip Reconstruction is further segmented into three types: Cemented Hip Reconstruction, Cementless Hip Reconstruction and Hybrid Hip Reconstruction.

United kingdomLaura woodStryker corporationE st office hours callOffice hours callZimmer biomet holdings incCompany profilesReconstruction marketPrimary total hip reconstructionPartial hip reconstructionHip resurfacingRevision hipCemented hip reconstructionCementless hip reconstructionHybrid hipZimmer biomet holdings